CMB International Global Markets | Equity Research | Company Update

Great Wall Motor (2333 HK)

4Q22E NP to fall YoY despite better sales mix

We project Great Wall Motor's 4Q22E net profit to decline 4% YoY to RMB 1.7bn amid its sales volume miss. We are of the view that investors could pay more attention to Great Wall's NEV sales volume growth rather than its profitability in FY23E. We think Great Wall has the right strategy to prioritize its NEV market share rather than profitability. We maintain BUY rating, although we prefer Geely (175 HK, BUY) over Great Wall among incumbent Chinese automakers.

- 4Q22E earnings preview. Great Wall's 4Q22 sales volume fell 33% YoY, lower than our prior expectation, largely due to its previous high inventories as noted in our earlier reports. We project its revenue in 4Q22E to decline 24% YoY amid better product mix. We also forecast its gross margin in 4Q22E to narrow 3 ppts QoQ to 19.5% due to year-end wage cost and heightened incentive costs. Accordingly, we estimate Great Wall's 4Q22E net profit to drop 4% YoY to RMB 1.7bn. Such profitability could still meet the criteria for its FY22 share option and restricted share schemes, although its sales volume fell short of its original target.
- NEV sales would be key to Great Wall in FY23. We are of the view that investors could pay more attention to Great Wall's NEV sales volume growth rather than its profitability in FY23E given its lagging in electrification. NEVs only accounted for 12% of Great Wall's total sales volume in FY22. The majority of its 18 scheduled new models in 2023 are PHEVs. We think Great Wall has the right strategy to prioritize its NEV market share rather than profitability. We expect its PHEV retail prices to be more competitive in 2023 with the lessons learnt from its too expensive Wey PHEVs in 2022. Therefore, we project NEV sales volume at Great Wall to more than double to 285,000 units in FY23E, or 23% of our projected 1.25mn-unit total sales. We also forecast Great Wall's FY23E net profit to decline 35% YoY to RMB 6.4bn.
- Valuation/Key risks. Great Wall's H-share price has risen about 50% since its low in Oct 2022. We maintain our BUY rating and raise our target price from HK\$ 10.00 to HK\$13.00, which is based on 16x our revised FY23E P/E amid improving investor sentiment toward China auto sector. It is also similar to the valuation that we assign to Geely's businesses excluding Zeekr. Possible positive catalyst for the share price could be sales beat from its upcoming 18 new models. Key risks to our rating and target price include lower sales volume and margins and slower tech transformation than we expect.

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	103,308	136,405	134,059	158,077	185,777
YoY growth (%)	7.4	32.0	(1.7)	17.9	17.5
Net income (RMB mn)	5,362	6,726	9,863	6,433	8,980
EPS (RMB)	0.58	0.73	1.07	0.69	0.96
YoY growth (%)	19.2	25.4	46.6	(34.8)	39.6
P/E (x)	15.6	12.1	8.8	13.7	9.9
P/B (x)	1.5	1.3	1.2	1.1	1.0
Yield (%)	3.7	1.3	4.2	2.8	3.8
ROE (%)	9.6	11.3	14.7	8.5	10.9
Net gearing (%)	12	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates



BUY (Maintain)

Target Price	HK\$ 13.00
(Previous TP	HK\$ 10.00)
Up/Downside	+18.2%
Current Price	HK\$ 11.00

China Auto Sector

SHI Ji, CFA (852) 3761 8728 shiji@cmbi.com.hk

DOU Wenjing, CFA (852) 6939 4751

douwenjing@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	95,130
Avg 3 mths t/o (HK\$ mn)	545
52w High/Low (HK\$)	21.57/6.90
Total Issued Shares (mn)	9,241
Source: Bloomberg	

Shareholding Structure

Wei Jianjun	56.4%
Others	43.6%
Source: HKEx	

Share Performance

	Absolute	Relative
1-mth	9.6%	-1.9%
3-mth	30.0%	-20.3%
6-mth	-10.0%	-19.5%
Source: Bloomberg		

12-mth Price Performance



Auditor: Deloitte

Related Reports

"Great Wall Motor – 3Q22 beat: upcoming new models as key" – 24 Oct 2022



Figure 1: Quarterly results

<u> </u>										
RMB mn	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22	4Q22E	YoY	QoQ
Sales volume (units)	325,798	288,591	265,834	396,948	283,500	229,053	283,788	265,210	-33.2%	-6.5%
ASP (RMB)	95,510	106,765	108,597	114,895	118,587	124,490	131,599	130,381	13.5%	-0.9%
Revenue	31,117	30,811	28,869	45,607	33,619	28,515	37,346	34,578	-24.2%	-7.4%
Gross profit	4,707	5,357	4,995	6,979	5,776	5,644	8,392	6,738	-3.4%	-19.7%
R&D expenses	(908)	(950)	(999)	(1,633)	(1,324)	(1,853)	(1,530)	(1,359)	-16.8%	-11.2%
SG&A expenses	(2,715)	(2,928)	(3,535)	(4,547)	(3,553)	(4,053)	(4,414)	(3,881)	-14.6%	-12.1%
Operating profit	1,864	1,995	1,420	1,090	1,341	3,962	2,743	1,453	33.3%	-47.0%
Net profit	1,639	1,889	1,416	1,781	1,634	3,967	2,560	1,703	-4.4%	-33.5%
Gross margin	15.1%	17.4%	17.3%	15.3%	17.2%	19.8%	22.5%	19.5%	4.2 ppt	-3.0 ppt
Operating margin	6.0%	6.5%	4.9%	2.4%	4.0%	13.9%	7.3%	4.2%	1.8 ppt	-3.1 ppt
Net margin	5.3%	6.1%	4.9%	3.9%	4.9%	13.9%	6.9%	4.9%	1.0 ppt	-1.9 ppt

Source: Company data, CMBIGM estimates

Figure 2: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	134,059	158,077	185,777	146,637	155,590	188,184	-8.6%	1.6%	-1.3%
Gross Profit	26,551	26,486	32,299	28,882	27,971	34,027	-8.1%	-5.3%	-5.1%
Operating Profit	9,499	6,368	9,462	10,342	8,247	10,964	-8.2%	-22.8%	-13.7%
Net profit	9,863	6,433	8,980	10,377	8,054	10,227	-4.9%	-20.1%	-12.2%
Gross Margin	19.8%	16.8%	17.4%	19.7%	18.0%	18.1%	0.1 ppt	-1.2 ppt	-0.7 ppt
Operating Margin	7.1%	4.0%	5.1%	7.1%	5.3%	5.8%	0.0 ppt	-1.3 ppt	-0.7 ppt
Net Margin	7.4%	4.1%	4.8%	7.1%	5.2%	5.4%	0.3 ppt	-1.1 ppt	-0.6 ppt

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

		CMBIGM			Consensus	;		Diff (%)	
RMB mn	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	134,059	158,077	185,777	151,643	191,446	230,185	-11.6%	-17.4%	-19.3%
Gross Profit	26,551	26,486	32,299	29,451	35,957	44,228	-9.8%	-26.3%	-27.0%
Operating Profit	9,499	6,368	9,462	10,991	11,282	13,905	-13.6%	-43.6%	-32.0%
Net profit	9,863	6,433	8,980	10,155	9,950	12,033	-2.9%	-35.3%	-25.4%
Gross Margin	19.8%	16.8%	17.4%	19.4%	18.8%	19.2%	0.4 ppt	-2.0 ppt	-1.8 pp
Operating Margin	7.1%	4.0%	5.1%	7.2%	5.9%	6.0%	-0.2 ppt	-1.9 ppt	-0.9 pp
Net Margin	7.4%	4.1%	4.8%	6.7%	5.2%	5.2%	0.7 ppt	-1.1 ppt	-0.4 pp

Source: Bloomberg, CMBIGM estimates



Financial Summary

Income statement

Income statement					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	103,308	136,405	134,059	158,077	185,777
Cost of sales	(85,531)	(114,367)	(107,508)	(131,591)	(153,478)
Gross profit	17,777	22,037	26,551	26,486	32,299
o	(1.100)	(= (= =)	(= == ()	(= ====)	(0.0.10)
Selling exp.	(4,103)	(5,192)	(5,074)	(5,752)	(6,346)
Admin exp. (ex. R&D)	(2,553)	(4,043)	(4,762)	(4,832)	(5,432)
R&D exp.	(3,067)	(4,490)	(6,066)	(6,411)	(8,157)
Others	(2,301)	(1,944)	(1,150)	(3,123)	(2,901)
Operating profit	5,752	6,369	9,499	6,368	9,462
Non-operating income	494	1,161	1,300	1,000	900
Non-operating exp.	(18)	(47)	(30)	(30)	(30)
Pre-tax profit	6,227	7,482	10,769	7,338	10,332
Тах	(865)	(757)	(915)	(917)	(1,343)
Minority interests	-	1	10	13	(9)
Net profit	5,362	6,726	9,863	6,433	8,980

Cash flow summary

VE 04 Dec (DMD mm)			EVOOE	EVONE	EVO 4E
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Profit before taxation	6,227	7,482	10,769	7,338	10,332
Depreciation/amortization	4,430	5,083	5,968	7,068	8,509
Change in working capital	(4,138)	24,154	(15,449)	6,655	3,176
Others	(1,338)	(1,403)	3,685	1,506	(258)
Net cash from operating	5,181	35,316	4,973	22,566	21,759
_					
Capex	(8,062)	(13,091)	(8,533)	(9,696)	(11,053)
Others	(3,527)	1,916	1,055	2,096	2,304
Net cash from investing	(11,588)	(11,175)	(7,478)	(7,600)	(8,749)
Net borrowings	13,817	(92)	(5,021)	(1,350)	(1,400)
Dividend paid	(2,538)	(5,878)	(1,860)	(2,410)	(3,046)
Others	89	(3,662)	289	500	950
Net cash from financing	11,368	(9,632)	(6,592)	(3,260)	(3,496)
Net change in cash	4,960	14,509	(9,097)	11,707	9,514
-		-	••••		,
Cash at beginning of the year	8,777	13,591	27,908	18,811	30,518
FX effect	(146)	(192)	-	-	-
Cash at the end of the year	13,591	27,908	18,811	30,518	40,032

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Current assets	99,399	108,366	98,683	117,450	136,397	Sales mix (%)					
Cash & equivalents	14,588	33,048	23,951	35,658	45,171	Sales of vehicles	89.4	88.9	87.4	88.7	89.6
Account receivables	58,448	41,497	45,911	51,970	61,077	Sales of parts	5.0	5.0	5.7	4.9	4.4
Inventories	7,498	13,966	11,782	12,618	12,615	Sales of moulds	1.2	1.6	1.9	1.9	1.8
Other current assets	18,865	19,854	17,040	17,204	17,534	Others	4.4	4.4	4.9	4.5	4.2
Non-current assets	54,613	67,042	69,084	71,843	74,440	Growth (%)					
PP&E	28,609	27,441	27,234	25,957	24,409	Revenue	7.4	32.0	(1.7)	17.9	17.5
Intangibles	5,543	7,091	8,550	10,175	11,925	Gross profit	7.6	24.0	20.5	(0.2)	21.9
Equity investments	8,415	9,524	11,268	12,092	13,173	Operating profit	20.4	10.7	49.1	(33.0)	48.6
Other non-current assets	12,045	22,986	22,032	23,621	24,933	Net profit	19.2	25.4	46.6	(34.8)	39.6
Total assets	154,011	175,408	167,767	189,293	210,837						
						Profit & loss ratio (%)					
Current liabilities	81,166	95,597	77,601	93,891	109,084	Gross margin	17.2	16.2	19.8	16.8	17.4
Bank borrowings	10,633	8,721	3,000	3,000	3,000	Operating margin	5.6	4.7	7.1	4.0	5.1
Payables	59,275	74,793	61,854	75,710	88,302	Net profit margin	5.2	4.9	7.4	4.1	4.8
Contract liabilities	8,028	7,388	8,815	10,394	12,215						
Other current liabilities	3,230	4,695	3,932	4,787	5,566	Balance sheet ratio					
						Net cash (debt)/total equity (x)	(0.1)	0.2	0.2	0.3	0.4
Non-current liabilities	15,504	17,683	18,345	16,686	15,049	Current ratio (x)	1.2	1.1	1.3	1.3	1.3
Bank borrowings	10,777	8,917	9,917	8,917	7,917	Receivable turnover days	207	111	125	120	120
Deferred income	3,462	4,113	4,082	4,055	4,031	Inventory turnover days	32	45	40	35	30
Other non-current liabilities	1,265	4,652	4,345	3,714	3,100	Payable turnover days	253	239	210	210	210
Total liabilities	96,670	113,280	95,946	110,577	124,133						
						Profitability (%)					
Share capital	9,176	9,236	9,282	9,340	9,458	ROE	9.6	11.3	14.7	8.5	10.9
Reserves	48,166	52,553	62,245	69,165	77,096	ROA	4.0	4.1	5.7	3.6	4.5
Minority interests	-	4	(6)	(19)	(10)						
Shareholders' equity	57,342	62,128	71,822	78,716	86,705	Per share data (RMB)					
Total equity and liabilities	154,011	175,408	167,767	189,293	210,837	EPS	0.58	0.73	1.07	0.69	0.96
						DPS	0.28	0.30	0.48	0.31	0.43

Source: Company data, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.